Replies to post #36163 on PharmaCyte Biotech Inc (PMCB)

[JDT188]

They have already stated that the results from the first preclinical were very positive. Now, instead of stating whether the results of the second trial are good, or bad, they state nothing and initiate a third test. IMO if the results were not favorable in the third test, they would have stated some of the positives from trial two. They are purposely not releasing testing information at this point. A close friend (MD/oncology) is attending the conference in Chicago this weekend. She said the companies are like "vultures" with their products, including big and small pharmas. The release of the third trial was strategically released the Friday before. Also, let's not forget Mr. Liquard coming on board towards the end of the second trial. So, as stated earlier, why would a CEO/Pfizer guy choose to join a board w a bad product. It's kinda like a CSI episode. You gotta try to connect the dots. And go......bashes

[BioNewton]

Nope. They trade on the Nasdaq and already have a pipeline. Show me one of the OTC's you were talking about that is already ahead of PMCB.

EMU will be right behind the FDA when fast-tracked. Oh, we have Orphan Drug Designation with the FDA pending our results where they are trying to pinpoint how much of the other cancer fighting drugs need to be used for CiaB which we know already works flawlessly. Fast-track will also follow GMP of our facility at Austrianova. Everyone educated on PMCB knows that.

[BioNewton]

Poor pick in NVIV. They were granted "conditional approval" in 2013 which is before 2014. Also dealt with a Class action lawsuit for most of 2014. So other than the Class Action lawsuit, PMCB seems to be right on track. Give us another please.